# Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

> **NCT02136797** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 77 (actual)

## Conditions studied

- CMV Infection
- Persistent CMV Viremia

## Interventions

- **BIOLOGICAL:** CMVpp65 Specific T-cells

## Key facts

- **NCT ID:** NCT02136797
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-08
- **Primary completion:** 2024-02-08
- **Final completion:** 2024-02-08
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2024-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02136797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02136797, "Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02136797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*